Pharmacogenomics Market 2025-2029: Unveiling Growth Developments with the Latest Updates

 Whether you’re expanding or optimizing within the pharmacogenomics industry, this report offers the clarity and context needed for confident decision-making.

 

 How Fast Is The Pharmacogenomics Market Growing Towards 2025?
 The pharmacogenomics market size has grown rapidly in recent years. It will grow from $8.94 billion in 2024 to $9.84 billion in 2025 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to strong economic growth in emerging markets, the increasing focus on personalized medicine, the rising advanced healthcare infrastructure and increased healthcare expenditure.
 
 The pharmacogenomics market size is expected to see rapid growth in the next few years. It will grow to $14.53 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to the increasing aging population, the increasing chronic diseases, the rising population and the increasing demand for cancer treatment. Major trends in the forecast period include launch of genome editing solution for deeper analysis of advanced therapies, focus on integration of artificial intelligence (AI) in genomics to analyze genetic data, growing advancements in metagenomics, strategic partnerships and collaborations among market players, introduction of three-dimensional (3D) genomics to study influences on gene expression and function, new product innovations with focus on infectious diseases and gene editing and development of psychotropic pharmacogenomics test for informed decisions.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp
 
 Pharmacogenomics Market Drivers And Opportunities
 The rising demand for precision medicine is driving the demand for the pharmacogenomics market. Precision medicine is a medical model that proposes healthcare customization, with medical decisions, treatments, practices, or products tailored to a subset of patients rather than a one-drug-fits-all model. There is a rising demand for precision medicine as it is the most advanced in oncology, having wider, exciting applications beyond oncology and late-stage diseases such as rare and genetic diseases. The main aim of precision medicine is to integrate genetic and environmental information about particular diseases and/or their responses to particular treatments. For instance, according to the article published on Linchpinseo in March 2022, the increasing demand for precision medicine investment from leading pharmaceutical companies is experiencing a 1/3 increase in the next five years. Furthermore, in the USA, 30 million people with type 2 diabetes get diagnosed and treated where precision medicine provides individualized treatment and will re-calibrate current treatment practices. Hence, the increasing demand for precision medicine will drive the pharmacogenomics market.
 
 How Is The Pharmacogenomics Market Segmented?
 The pharmacogenomics market covered in this report is segmented — 
 
 1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies
 2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications
 3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users
 
 Subsegments:
 1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing 
 2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR 
 3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis 
 4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry) 
 5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays 
 6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools 
 
 What Are The Key Trends And Market Opportunities In The Pharmacogenomics Sector?
 Technological advancement is a key trend gaining the popularity in pharmacogenomics market. Medicine manufacturers are focusing on various approaches to pharmacogenomics analysis to provide cost-effective solutions for screening known polymorphisms and the discovery of novel variants. For instance, in May 2022, Invitae, a US-based medical laboratory organization, launched its expanded Pharmacogenomics Panel. The Invitae Pharmacogenomics (PGx) Panel, including the Mental Health Panel, provides insights into genetic responses to medications across various specialties like primary care, cardiology, and oncology. With nearly 25% of patients facing atypical drug responses due to genetics, PGx testing is set to become a standard practice. Effective integration into healthcare requires enhanced support for providers to understand and apply PGx testing in their clinical settings. 
 
 Major Companies Operating In The Pharmacogenomics Market Are:
 Major companies operating in the pharmacogenomics market include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, PerkinElmer Inc, Centogene N.V, Invitae Corporation, Genomind, Pacific Biosciences of California Inc, Oneome LLC, Admera Health, MapMyGenome, Positive Bioscience, Xcode Life Sciences, Xcelris Labs, Takeda Pharmaceutical Company Limited, Garvan Institute of Medical Research, 3D Medicines Inc, Berry Genomics, BGI, GenomiCare Biotechnology, Bayer AG, GlaxoSmithKline plc (GSK), F Hoffmann-La Roche AG, Merck KGaA, QIAGEN N.V, Centro de Genoma e Biologia de Sistemas (CGBS), Dasa Group, Datar Cancer Genetics Limited, MedGenome Labs, 23andMe, Color Genomics, Pathway Genomics, Laboratório Richet, Laboratório Exame, Genomika Diagnósticos 
 
 View the full pharmacogenomics market report here:
 https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report
 
 Regional Analysis: Opportunities And Challenges In The Pharmacogenomics Market
 North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company